Skip to content

Nightime NIV Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting

Nightime Noninvasive Mechanical Ventilation Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting. A Non-inferiority Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02759003
Enrollment
50
Registered
2016-05-03
Start date
2011-03-31
Completion date
2014-03-31
Last updated
2016-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Brief summary

In patients with amyotrophic lateral sclerosis (ALS), non-invasive mechanical ventilation (NIV) is usually initiated in an in-hospital regime. The investigators evaluated if NIV initiated in an outpatient setting can be as effective as regards patients' adherence. The investigators also evaluated factors predicting NIV adherence and disease progression.

Detailed description

All patients with a definite ALS diagnosis, aged \> 18 years, referred to the ALS outpatient clinics of the Fondazione Salvatore Maugeri Institute of Lumezzane (Brescia) and Istituto Don Gnocchi Onlus (Milano), Italy, for respiratory functional assessments for the purpose of early initiation of NIV were considered. Patients who were in clinically stable condition and without chest infections during the previous 3 months were considered eligible for the study. Between March 2011 and March 2014, during an outpatient visit, the patients were randomized 1:1 to two groups for NIV initiation: outpatient vs. inpatient protocol. In both groups a diurnal NIV initiation trial was performed using pressure-support ventilators in spontaneous/timed mode with a preset tidal volume (300 ml/kg) and a fixed back-up respiratory rate (12 breaths/min). The trial included: choice of the mask, setting of ventilator pressure, at least 2 hours of NIV under supervision. Then, the patients underwent the nighttime NIV initiation trial for a maximum of 20 nights according to the outpatient vs. inpatient protocol. NIV trial was stopped when: 1) patients used NIV \> 4 hours/night for 3 consecutive nights, 2) patients and caregivers were able to manage with ventilator, 3) patients failed after 10 consecutive educational sessions. At enrollment (T0), the end of NIV initiation trial (T1) and after 3 months from the end of the trial (T2) respiratory function tests, blood gas analysis, and sleep study were performed. At T1 the investigators assessed NIV acceptance (as a minimum of 3 consecutive days \>4 h/night), and dyspnea symptoms by VAS (day/night), staff and patients' satisfaction. At T2: NIV adherence (\>120 h/month) and patients' satisfaction.

Interventions

PROCEDURENightime NIV initiation

In-hospital vs home

Sponsors

Fondazione Don Carlo Gnocchi Onlus
CollaboratorOTHER
Fondazione Salvatore Maugeri
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* consecutive patients * definite ALS diagnosis * aged \> 18 years * in clinically stable condition * referred to the ALS outpatient clinics of the Fondazione Salvatore Maugeri Institute of Lumezzane (Brescia) and the Istituto Don Gnocchi Onlus (Milano), Italy for respiratory functional assessment for the purpose of early initiation of NIV * no chest infections during the previous 3 months.

Exclusion criteria

* cognitive impairment * refusal to participate * severe comorbidities and contraindications to NIV (arrhythmias, cardiac failure, history of pneumothorax) * distance from hospital \> 40 km, travel problems to attend the outpatient clinic

Design outcomes

Primary

MeasureTime frameDescription
Adherence as measured by the use of ventilator (hours/month)At 3 monthsEvaluation after 3 months from the end of NIV initiation trial (T2)

Secondary

MeasureTime frameDescription
Changes in respiratory function as assessed by spirometryAt 3 monthsEvaluation at 3 months from the end of NIV initiation trial (T2)
Changes in dyspnea symptoms as assessed by Visual Analogue ScaleAt 3 monthsEvaluation at 3 months from the end of NIV initiation trial (T2)
Patient's questionnaire of satisfactionAt 20 daysEvaluation at the end of NIV initiation trial (T1)
Changes in respiratory function as assessed by Maximal inspiratory pressure/Maximal expiratory pressureAt 3 monthsEvaluation at 3 months from the end of NIV initiation trial (T2)
Changes in respiratory function as assessed by blood gas analysisAt 3 monthsEvaluation at 3 months from the end of NIV initiation trial (T2)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026